Exchange & Returns Information
Review Details
(0)
| Generic For | NEXAVAR |
|---|---|
| Active Ingredient | SORAFENIB |
| Strength | 200MG |
| Manufacturer | SAMARTH LIFE SCIENCES |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 120 TABLETS | $ 1.10 | $ 132.00 |
$ 112.20
Apply ZARVY26 (-15%)
You save $ 19.80
|
||
| 2 BOXES - 240 TABLETS | $ 1.09 |
1% $ 264.00
$ 262.00
|
$ 222.70
Apply ZARVY26 (-15%)
You save $ 39.30
|
||
| ★ Best Value 3 BOXES - 360 TABLETS | $ 1.06 |
4% $ 396.00
$ 382.00
|
$ 324.70
Apply ZARVY26 (-15%)
You save $ 57.30
|
Reference information will be available soon.
Soratib 200 is an oral targeted therapy containing sorafenib 200 mg, a first-generation multikinase inhibitor (TKI) designed to disrupt both tumor cell proliferation and tumor angiogenesis.
Its mechanism involves inhibition of a broad spectrum of kinases, including RAF kinases, VEGFR, PDGFR, KIT, and RET, all of which are crucial for tumor growth and blood vessel development. By simultaneously blocking intracellular signaling and vascular pathways, sorafenib reduces both cancer cell survival and tumor vascularization.
Clinically, Soratib 200 is well-established in:
Hepatocellular carcinoma (HCC): a standard first-line option in advanced, unresectable cases, prolonging survival.
Renal cell carcinoma (RCC): used in advanced disease, especially after failure of cytokine-based therapy.
Differentiated thyroid carcinoma (DTC): effective in patients with radioactive iodine–refractory progressive disease.
Thanks to its oral formulation and systemic bioavailability, Soratib 200 is frequently used in long-term maintenance therapy for advanced solid tumors, offering continuous disease control with manageable toxicity under medical supervision.
AntiCancer Drugs > Hepatocellular Carcinoma (HCC)
Approved as a first-line systemic therapy for unresectable or metastatic HCC. Sorafenib works by blocking tumor angiogenesis and inhibiting proliferation pathways, thereby slowing disease progression. It has been shown to modestly extend overall survival in advanced-stage liver cancer and is recommended in major oncology guidelines.
AntiCancer Drugs > Renal Cell Carcinoma (RCC)
Indicated for advanced or metastatic RCC, particularly when surgical resection is not feasible. Sorafenib inhibits VEGFR and PDGFR, suppressing tumor blood vessel formation and cell growth. It is used as first- or second-line therapy, including in patients who have failed cytokine or immunotherapy regimens.
AntiCancer Drugs > Differentiated Thyroid Cancer (DTC)
Approved for patients with progressive, radioactive iodine (RAI)-refractory DTC. Sorafenib limits tumor vascularization and intracellular signaling, offering a non-surgical systemic option that helps control disease progression in advanced thyroid cancer.
AntiCancer Drugs > Off-label Uses & Research Applications
Actively studied and used off-label in non-small cell lung cancer (NSCLC), breast cancer, pancreatic carcinoma, and other solid tumors. Sorafenib is frequently tested in combination regimens and resistance-mitigation protocols, expanding its potential role in advanced oncology treatment strategies.
Sorafenib acts through a dual inhibitory mechanism that targets both tumor proliferation and angiogenesis:
RAF/MEK/ERK pathway blockade: By inhibiting RAF kinases, sorafenib disrupts downstream signaling critical for cell cycle progression, growth, and survival.
Receptor tyrosine kinase inhibition: Sorafenib blocks VEGFR and PDGFR, preventing angiogenesis and thereby cutting off the tumor’s blood supply.
This combined effect suppresses tumor growth, invasion, and vascular development, while also impacting tumor metabolism and cell cycle regulation.
Administered orally, sorafenib provides systemic bioavailability that supports continuous long-term therapy, offering practicality for outpatient management. Unlike conventional cytotoxic chemotherapy, sorafenib selectively targets cancer-driving pathways, reducing nonspecific damage to normal cells and enabling more focused cancer control.
Adults – Hepatocellular Carcinoma (HCC): 400 mg orally twice daily
Renal Cell Carcinoma (RCC): 400 mg orally twice daily
Differentiated Thyroid Cancer (DTC): 400 mg orally twice daily
Administration:
Take on an empty stomach (≥1 hour before or ≥2 hours after meals) with a full glass of water
Do not crush or chew tablets
Continue therapy until disease progression or unacceptable toxicity
Monitoring:
Liver function tests
Blood pressure
Signs of bleeding
Hand-foot skin reaction
Dose Adjustments:
May be required for skin toxicity, diarrhea, or hypertension
Drug Interactions & Restrictions:
Avoid strong CYP3A4 inducers/inhibitors unless under medical supervision
Do not consume grapefruit or grapefruit juice (alters drug metabolism)
Store at room temperature below 25°C in a dry place
Keep tablets in the original blister pack until use
Protect from moisture, direct sunlight, and excessive heat
If using a bottle pack, ensure the cap is tightly closed after each use
Keep out of reach of children
Common: hand-foot skin reaction, rash, diarrhea, fatigue, hypertension, weight loss
Severe: gastrointestinal perforation, liver dysfunction, cardiac ischemia, hemorrhagic events
Other reported: thyroid dysfunction, delayed wound healing (long-term use)
Monitoring: regular checks for skin toxicity, blood pressure, liver function, bleeding signs
Stop and seek medical help if: severe abdominal pain, chest pain, unusual bleeding, or yellowing of the eyes occurs
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
